Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.4K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.4K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

213
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
213
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

139
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
139

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benign Lesions Scored as O-RADS US v2022 4 and 5 Categories: Prevalence and Morphologic Analysis.

Radiology·2026
Same author

MRI and Clinical Features of Nonenhancing <i>IDH</i>-Wild-Type Glioblastomas: How to Make an Early Diagnosis and Distinguish from Mimics.

AJNR. American journal of neuroradiology·2026
Same author

Comprehensive Review of the Imaging of Adult Facial Nerve Reanimation.

AJNR. American journal of neuroradiology·2026
Same author

Working in concert: radiology, pathology, and gynecologic oncology applications of the 2023 FIGO updates in endometrial cancer staging.

Abdominal radiology (New York)·2026
Same author

Maintaining scientific rigor in clinical imaging science - 2026.

Journal of clinical imaging science·2026
Same author

EFSUMB Guidelines on Multiparametric Ultrasound of the Scrotum.

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Aug 10, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Prostate Cancer-PET Imaging Update.

Sankarsh Jetty1, James Ryan Loftus1, Abhinav Patel2

  • 1Department of Imaging Sciences, University of Rochester Medical Center, New York, NY 14642, USA.

Cancers
|February 11, 2023
PubMed
Summary
This summary is machine-generated.

New molecular imaging agents, including Fluorine-18 fluciclovine (Axumin) and PSMA-ligand agents, offer improved evaluation options for prostate cancer recurrence. These advancements aid in assessing this common cancer, despite treatment advancements.

Keywords:
AxuminPETPSMAbiochemical recurrenceprostate cancer

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

325
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.0K

Related Experiment Videos

Last Updated: Aug 10, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

325
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.0K

Area of Science:

  • Oncology
  • Radiology
  • Nuclear Medicine

Background:

  • Prostate cancer is a leading cause of cancer mortality in men, with incidence rising after age 65.
  • Variable aggressiveness based on grade and stage necessitates accurate diagnostic tools.
  • Despite treatment advances, 25% of patients experience prostate cancer recurrence.

Purpose of the Study:

  • To review commonly used molecular imaging agents for prostate cancer evaluation.
  • To emphasize Fluorine-18 fluciclovine (Axumin) and PSMA-ligand agents.
  • To discuss protocols, interpretation, and potential pitfalls of these imaging agents.

Main Methods:

  • Review of current literature on prostate cancer molecular imaging.
  • Focus on Positron Emission Tomography (PET) agents approved by the FDA.
  • Analysis of imaging protocols, interpretation guidelines, and common challenges.

Main Results:

  • Recent FDA approvals have expanded options for prostate cancer imaging.
  • Fluorine-18 fluciclovine (Axumin) and PSMA-ligand agents are key advancements.
  • Understanding protocols and interpretation is crucial for effective use.

Conclusions:

  • Molecular imaging, particularly with Axumin and PSMA-ligands, provides new avenues for evaluating prostate cancer.
  • Accurate interpretation and awareness of pitfalls are essential for clinical application.
  • These PET agents represent significant progress in managing prostate cancer recurrence.